`ESTTA1297174
`07/13/2023
`
`ESTTA Tracking number:
`
`Filing date:
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
`Applicants
`
`Application serial no.
`
`Application filing date
`
`Mark
`
`Date of publication
`
`Potential opposer's
`Correspondence information
`
`Jiangsu CF PharmTech Co., Ltd.
`
`97390324
`
`04/30/2022
`
`AUROAIR
`
`06/20/2023
`
`LAURENCE RICKLES
`TEVA PHARMACEUTICAL INC
`400 INTERPACE PARKWAY
`PARSIPPANY, NJ 07054
`UNITED STATES
`Primary email: laurence.rickles@tevapharm.com
`Secondary email(s): maur-
`een.manson@tevapharm.com, trade-
`marks.trademarks@tevapharm.com
`No phone number provided
`
`First 90 Day Request for Extension of Time to Oppose for Good
`
`Cause
`
`Pursuant to 37 C.F.R. Section 2.102, Teva Pharmaceutical Inc, 400 Interpace Parkway, Parsippany, NJ
`07054, UNITED STATES, a corporation organized under the laws of United States, respectfully requests that
`it be granted a 90-day extension of time to file a notice of opposition against the above-identified mark for
`cause shown.
`Potential opposer believes that good cause is established for this request by:
`- The potential opposer needs additional time to investigate the claim
`The time within which to file a notice of opposition is set to expire on 07/20/2023. Teva Pharmaceutical Inc re-
`spectfully requests that the time period within which to file an opposition be extended until 10/18/2023.
`Respectfully submitted,
`/laurencerickles/
`Laurence Rickles
`laurence.rickles@tevapharm.com, maureen.manson@tevapharm.com
`07/13/2023
`
`



